Dr. Robert J. Soiffer, MD

Dr. Soiffer practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Soiffer's NPI, 1780653261, was assigned on March 16, 2006. Dr. Soiffer graduated from New York University School of Medicine in 1983. Dr. Soiffer holds Massachusetts license 56125.

Dr. Soiffer's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Soiffer's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Soiffer is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Soiffer to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soiffer practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Soiffer's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Soiffer is licensed in Massachusetts.

CMS data shows 379 Medicare services from Dr. Soiffer across 4 procedure codes in 2024, for 154 Medicare patients. Medicare paid $30,446 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 154 Medicare patients who saw Dr. Soiffer in 2024. The largest group is 65 to 74, with 95 patients. 70% of them have high cholesterol, and 64% have high blood pressure. 9% are also on Medicaid. Their average risk score is 3.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Soiffer's median patient age at 69, with 45% women.

In 2024, Dr. Soiffer wrote 484 Medicare Part D claims for 85 patients. 64% of them were for generic drugs. CMS names the drug for 344 of them, across 9 drugs with 11 or more claims each, at $2,596,901 in total drug cost. In 2023, CMS named 465 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Soiffer for performance year 2024, reported as part of a group. Dr. Soiffer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Soiffer as offering telehealth.

Dmand AI links 252 papers to Dr. Soiffer, published from 2010 to 2025. 2016 was the busiest year, with 20. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Transplantation, Homologous. Dr. Soiffer has published most often in Biol Blood Marrow Transplant. Dr. Soiffer's most frequent co-authors are Vincent Trien-Vinh Ho, MD, Joseph Harry Antin, MD and John Koreth, MBBS.

Dmand AI links Dr. Soiffer to 3 clinical trials, 3 of them phase 1 studies. Conditions studied include Bronchiolitis Obliterans Syndrome, Leukemia, Myelomonocytic, Chronic and Myelodysplastic-Myeloproliferative Diseases. Massachusetts General Hospital sponsors the most, 2.

CMS Open Payments shows 159 general payments to Dr. Soiffer from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 87% of the total. Bristol-Myers Squibb Company paid the most, $48,650. It also lists 1 research payment totaling $1,600 in 2017.

Dr. Soiffer graduated from New York University School of Medicine in 1983.